Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital

BACKGROUND: Sorafenib is first line chemotherapy for advanced hepatocellular carcinoma (HCC). There are little real-world experiences with sorafenib done on US population except for the US arm of the GIDEON study, a phase IV multi-national study. In this context, we present a single institution expe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Gastrointest Oncol
Glavni autori: Mukthinuthalapati, V. V. Pavan Kedar, Wang, Yuchen, Abu Omar, Yazan, Syed, Moin, Attar, Bashar
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6219969/
https://ncbi.nlm.nih.gov/pubmed/30505582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.06.09
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items